SOLICITATION NOTICE
Q -- Variability in the efficacy of oral cancer screening according to risk of oral cancer within Oral Cancer Screening Trials
- Notice Date
- 6/25/2015
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52620-24
- Archive Date
- 7/24/2015
- Point of Contact
- Kimesha Leake, Phone: 2402765669, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
kimesha.leake@nih.gov, gallowaytl@mail.nih.gov
(kimesha.leake@nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP), Infections and Immunoepidemiology Branch (IIB) plans to procure on a sole source statistical analyses using data from IARC's Kerala Oral Cancer Screening Trial to investigate variability in the efficacy of screening according to participants' predicted risk of oral cancer from the International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon cedex 08, France. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Oral cancers are ideal candidates for screening, early detection, and secondary prevention given their amenability for visual inspection and specimen collection as well as the availability of recognized precursor lesions. Only one randomized trial to date has investigated whether visual screening for oral cancer precursors or cancer reduced oral cancer mortality. This community-based, cluster-randomized trial of 191,872 individuals conducted in Kerala, India, showed sustained reduction in oral cancer mortality over 15 years of follow-up among screened individuals as compared with individuals who were not screened. More importantly, the trial showed that the benefit of visual screening was observed almost exclusively among individuals with traditional oral cancer risk factors-cigarette smokers, tobacco chewers, or alcohol users. The results of the Kerala screening trial underscore that the efficacy of visual screening for oral cancer varies according to an individual's baseline risk of oral cancer. In that, individuals at high risk for oral cancer (e.g. smokers, chewers, and alcohol users) experienced all of the benefit from screening, while individuals at low-risk for oral cancer did not experience any benefit from screening. It is likely that even among the high risk group of smokers, chewers, and alcohol users, there would be further variability in the efficacy of visual screening, with the benefits accruing among the highest risk individuals. The NCI proposes to enter into a contract with researchers at the International Agency for research on Cancer to develop and utilize oral cancer risk prediction models to identify a subgroup of individuals in the Kerala screening trial who experienced the maximum benefit from visual inspection. IARC is the only source of data on the Kerala oral cancer screening trial. There has only been one trial conducted to date on this topic, and this trial was conducted by IARC. IARC is necessary to continue an ongoing project; a change would be disruptive to the experiment. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 3:00 PM EST, on July 9, 2015. All responses and questions must be in writing and faxed 240-276-5401 or emailed to Kimesha Leake, Contract Specialist OR via electronic mail at kimesha.leake@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP52620-24 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52620-24/listing.html)
- Place of Performance
- Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E626, Bethesda, MD 20892, UNITED STATES, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03776725-W 20150627/150625235846-433debf93e94cd4e1cde8942c1ed8930 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |